Your device
What the Stelo knows about you
Stelo by Dexcom is a continuous glucose monitor biosensor and the glucose-biometric entry in the cohort, recorded in the biometric form factor as a boundary include because glucose is in the biometric definition and Stelo pairs an FDA-cleared sensor with a genuine generative-AI insight layer rather than being a bare sensor readout. Made by DexCom (NASDAQ: DXCM) as a product line separate from its prescription G7 monitors, Stelo is the first-ever FDA-cleared over-the-counter, no-prescription continuous glucose biosensor, cleared via De Novo announced on March 5, 2024 and launched in the US on August 26, 2024 for adults 18 and older who are not on insulin, including people with type 2 diabetes not on insulin and non-diabetic users tracking the impact of diet and exercise, with a 15-day wear and no low-glucose alerts since it is not cleared for problematic hypoglycemia. Its AI augmentation is genuine: Dexcom launched a generative-AI platform for Stelo on Google Cloud's Vertex AI and Gemini, providing personalized Weekly Insights, AI photo meal logging, and up to three personalized daily recommendations drawn from glucose, activity, nutrition, and sleep, which is what tips it from a medical sensor to an in-definition biometric-AI device and fills the glucose cell distinct from the heart-rate and sleep watches and rings. Its FDA clearance makes it the strongest verification anchor of the Wave-2 set, while the marketing claim of being the first generative-AI platform in glucose biosensing is not load-bearing and is not asserted, and its exclusion of low-glucose alerting is recorded as an indication boundary.
Track the Stelo and we will tell you the moment its privacy, price, or safety record changes.
Track this device →What it knows about you
4 findings on record · 4 verified against primary sources
What it collects about you
Where your data goes
What you can control
What it collects about you
The data this device picks up.
Your body data
Continuously tracks your glucose levels and provides trend analysis, spike detection, and daily and weekly summaries. The app analyzes your readings alongside meals, exercise, sleep, age, and other factors to give personalized recommendations.
Where your data goes
Who else can see it once it leaves the device.
Training their AI
Dexcom uses your Stelo health data for internal research, bug fixes, product improvement, and regulatory compliance.
Shared with others
Google Play shows no data is shared with third parties, though data may be shared with affiliated companies and service providers for operations. A separate privacy policy from Edwards Health Care Services covers fulfillment data.
What you can control
Your say over the data it holds.
Deleting your data
You can request data deletion. Data is encrypted in transit. The app collects personal info including name, email, health data, crash logs, and device identifiers.
The full record
- Specs
- Stelo: continuous glucose monitor (CGM) biosensor, 15-day wear; first-ever FDA-cleared OTC (no-prescription) glucose biosensor (De Novo Mar 5 2024; US launch Aug 26 2024). Indication: adults 18+ NOT on insulin (type 2 not on insulin + non-diabetic users tracking diet/exercise impact); not cleared for problematic hypoglycemia (no low-glucose alerts). Generative-AI: Weekly Insights (Google Cloud Vertex AI + Gemini), AI photo meal logging, personalized daily recommendations. Company: DexCom Inc (NASDAQ: DXCM); Stelo = the OTC product line (separate from prescription G7).
- Form Factor
- biometric (biometric-primary GLUCOSE biosensor / OTC continuous glucose monitor + generative-AI insights)